| Analysis | Metabolite Name | Measured Value | Units | Genotype | Treatment | Metabolite | Tissue |
|---|---|---|---|---|---|---|---|
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.048 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.065 | mg/mL | F344 Pirc | AIN-93G (control) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.089 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.098 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.100 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.106 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.111 | mg/mL | F344 Pirc | AIN-93G (control) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.123 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.125 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.126 | mg/mL | F344 Pirc | AIN-93G (control) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.127 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.132 | mg/mL | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.137 | mg/mL | F344 Pirc | 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.141 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.144 | mg/mL | F344 Pirc | 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.144 | mg/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.150 | mg/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.150 | mg/mL | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.153 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.154 | mg/mL | F344 Pirc | 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.156 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.158 | mg/mL | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.161 | mg/mL | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.161 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.162 | mg/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.163 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.165 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.173 | mg/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.178 | mg/mL | F344 Pirc | AIN-93G (control) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.185 | mg/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.189 | mg/mL | F344 Pirc | AIN-93G (control) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.191 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.196 | mg/mL | F344 Pirc | 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.197 | mg/mL | F344 Pirc | AIN-93G (control) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.198 | mg/mL | F344 Pirc | AIN-93G (control) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.200 | mg/mL | F344 Pirc | 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.202 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.203 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.209 | mg/mL | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.221 | mg/mL | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.224 | mg/mL | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.235 | mg/mL | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.244 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.254 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.270 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.301 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.340 | mg/mL | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.383 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 0.387 | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Plasma |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 2.157 | mg/g tissue | F344 Pirc | 200 ppm Naproxen | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 2.531 | mg/g tissue | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 2.970 | mg/g tissue | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 3.219 | mg/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 3.830 | mg/g tissue | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 4.350 | mg/g tissue | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 4.719 | mg/g tissue | F344 Pirc | HD TP-252 (3% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 5.380 | mg/g tissue | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 5.501 | mg/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 5.623 | mg/g tissue | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 5.821 | mg/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 6.831 | mg/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 6.899 | mg/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 7.518 | mg/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | 8.370 | mg/g tissue | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Tumor-adjacent normal colon |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/g tissue | F344 Pirc | 200 ppm Naproxen | Fatty Acid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/g tissue | F344 Pirc | AIN-93G (control) | Fatty Acid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/g tissue | F344 Pirc | EPA-FFA (2%) + 200 ppm Naproxen | Fatty Acid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/g tissue | F344 Pirc | EPA-FFA (2% EPA) | Fatty Acid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/g tissue | F344 Pirc | HD TP-252 (3% EPA) + 200 ppm Naproxen | Fatty Acid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/g tissue | F344 Pirc | HD TP-252 (3% EPA) | Fatty Acid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Fatty Acid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/g tissue | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Tumor-adjacent normal colon | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/mL | F344 Pirc | 200 ppm Naproxen | Fatty Acid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/mL | F344 Pirc | HD TP-252 (3% EPA) | Fatty Acid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Fatty Acid | Plasma | |
| None (Direct infusion) NEGATIVE ION MODE | Dodecanoic acid | mg/mL | F344 Pirc | LD TP-252 (1.5% EPA) | Fatty Acid | Plasma |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|